Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease in urgent need of newer therapeutic modalities. Majority of patients with PDAC have mutations in KRAS, which unfortunately remains an ineffectual target. Our strategy here is to target KRAS downstream effectors PI3K and mTOR. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Changwen, Liang, Min, Liu, Shuang, Wang, Guan, Edwards, Holly, Xia, Yang, Polin, Lisa, Dyson, Gregory, Taub, Jeffrey W., Mohammad, Ramzi M., Azmi, Asfar S., Zhao, Lijing, Ge, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546481/
https://www.ncbi.nlm.nih.gov/pubmed/28574828
http://dx.doi.org/10.18632/oncotarget.17869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546481/
https://www.ncbi.nlm.nih.gov/pubmed/28574828
http://dx.doi.org/10.18632/oncotarget.17869

Ejemplares similares